ReviewUrologic oncology2019
The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer.
Review in Urologic oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Recent advances and future prospects of immunotherapeutic approaches in prostate cancer.Journal of translational medicine · 2026Review
- Review
- Tertiary lymphoid structures in genitourinary cancers: a comprehensive review.Frontiers in oncology · 2026Review
- Prostate cancer cell-derived exosomes inhibit macrophage phagocytosis through EIF3B-mediated exosomal sorting of miR-100-5p.Scientific reports · 2025Article
- Integrated proteogenomic characterization of localized prostate cancer identifies biological insights and subtype-specific therapeutic strategies.Nature communications · 2025Article
- DPT has potential to be a prognostic biomarker and its correlation with immune infiltrates in prostate cancer.American journal of clinical and experimental immunology · 2025Article
- CD8Nature communications · 2024Article
- Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responses.Clinical and experimental medicine · 2023Article
- High expression of centromere protein A and its molecular mechanism and clinical significance in prostate cancer: A study based on data mining and immunohistochemistry.IET systems biology · 2023Article
- Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.Nature communications · 2022Article
- Methylation Pattern Mediated by mOxidative medicine and cellular longevity · 2022Article
- Identification of Novel Diagnostic Biomarkers in Prostate Adenocarcinoma Based on the Stromal-Immune Score and Analysis of the WGCNA and ceRNA Network.Disease markers · 2022Article
- M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer.Annals of medicine · 2021Article
- The Role of Somatic Mutations on the Immune Response of the Tumor Microenvironment in Prostate Cancer.International journal of molecular sciences · 2021Review
- Comprehensive Analysis of the Relationship Between Metabolic Reprogramming and Immune Function in Prostate Cancer.OncoTargets and therapy · 2021Article
- Identification of immune cell infiltration pattern and related critical genes in metastatic castration-resistant prostate cancer by bioinformatics analysis.Cancer biomarkers : section A of Disease markers · 2021Article
- Identification of a Costimulatory Molecule-Related Signature for Predicting Prognostic Risk in Prostate Cancer.Frontiers in genetics · 2021Article
- Prognostic Significance of Gene Signature of Tertiary Lymphoid Structures in Patients With Lung Adenocarcinoma.Frontiers in oncology · 2021Article
- TGFβ1: An Indicator for Tumor Immune Microenvironment of Colon Cancer From a Comprehensive Analysis of TCGA.Frontiers in genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Immunotherapy-particularly immune checkpoint blockade-has seen great success in many tumor types. However, checkpoint-based therapies have not demonstrated high levels of success in prostate cancer, and there is much to be learned from both the successes and failures of these treatments. Here we review the evidence that composition of infiltrating immune cells in the tumor microenvironment is fundamental to the response to immunotherapy. Additionally, we discuss the emerging idea that the organization of these immune cells may also be crucial to this response. In prostate cancer, the composition and organization of the tumor immune microenvironment are preeminent topics of discussion and areas of important future investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.